EPCs and pathological angiogenesis: when good cells go bad.
EPCs and pathological angiogenesis: when good cells go bad.
复制标题
DOI：
10.1016/j.mvr.2010.02.011
复制
发表时间：
2010-05
影响因子：
3.1
通讯作者：
Grant MB
中科院分区：
文献类型：
--
作者：
Li Calzi S;Neu MB;Shaw LC;Kielczewski JL;Moldovan NI;Grant MB
骨髓来源的内皮祖细胞（EPCs）有助于血管生成介导的病理性新血管形成，最近的研究已经开始认识到这种贡献的生物学意义。这篇综述将讨论EPCs在生理和病理条件下促进新生血管形成的能力。循环EPCs最初由Asahara于1997年鉴定为CD34+ VEGFR2+单核细胞。这些细胞分化成内皮表型，表达内皮标志物，并在缺血部位并入新血管。内皮祖细胞提供指导性（释放促血管生成细胞因子）和结构性（血管整合和稳定）功能，有助于启动新血管生成。EPC群体可以基于新鲜分离的细胞的表面标志物来表征，或者一旦置于培养物中，它们可以通过它们的体外特征来描述。然而，该领域进展的一个主要障碍是研究人员对EPCs的最佳表征缺乏共识。本综述旨在探讨这两种内皮祖细胞的作用，并评估它们在病理性血管生成中如何相互作用。由于EPCs可能负责打开“血管生成开关”，因此已采用策略来将该开关保持在“关闭”位置，以治疗癌症、视网膜病和湿性AMD等疾病。预期EPCs将发展成为癌症和与病理性新血管形成相关的眼部疾病的临床有用的预后和预测工具，并且靶向这种细胞类型是成功管理患有与病理性新血管形成相关的疾病的患者的关键。
Bone marrow-derived endothelial progenitor cells (EPCs) contribute to angiogenesis-mediated pathological neovascularization and recent studies have begun to recognize the biological significance of this contribution. This review will discuss the ability of EPCs to contribute to neovascularization in both physiological and pathological conditions. Circulating EPCs were originally identified in 1997 by Asahara as CD34+ VEGFR2+ mononuclear cells. These cells differentiated into an endothelial phenotype, expressed endothelial markers, and incorporated into neovessels at sites of ischemia. EPCs provide both instructive (release of pro-angiogenic cytokines) and structural (vessel incorporation and stabilization) functions that contribute to the initiation of neo-angiogenesis. EPC populations can be characterized based on surface markers of freshly isolated cells or they can be described by their in vitro characteristics once placed in culture. However, a major stumbling block to progress in the field has been the lack of consensus among investigators as to the optimal characterization of EPCs. This review intends to address the role of both EPC classes and evaluate how they interact in the setting of pathological angiogenesis. Since the EPCs may be responsible for turning on the “angiogenic switch,” strategies have been employed to keep this switch in the “off” position for diseases like cancer, retinopathy and wet AMD. The expectation is that EPCs will evolve into clinically useful prognostic and predictive tools in cancer and in ocular diseases associated with pathological neovascularization and that targeting this cell type is a key to successful management of patients suffering from diseases associated with pathological neovascularization.
登录
查看更多内容
影响因子：
56.9
作者：
Asahara, T;Murohara, T;Isner, JM
通讯作者：
Isner, JM
影响因子：
--
作者：
Kern, Timothy S.
通讯作者：
Kern, Timothy S.
影响因子：
2.8
作者：
Cursiefen, C;Maruyama, K;Kruse, FE
通讯作者：
Kruse, FE
影响因子：
7.7
作者：
Caballero, Sergio;Sengupta, Nilanjana;Grant, Maria B.
通讯作者：
Grant, Maria B.
影响因子：
6.2
作者：
Dorrell, Michael I.;Aguilar, Edith;Jacobson, Ruth;Trauger, Sunia A.;Friedlander, Jeffrey;Siuzdak, Gary;Friedlander, Martin
通讯作者：
Friedlander, Martin